Cells for characterization of botulinum neurotoxins
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 6, 2024
Grant Date -
Jan 4, 2024
app pub date -
Apr 21, 2023
filing date -
Oct 16, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
Recombinant nucleic acids encoding reporting constructs for characterizing botulinum neurotoxin protease activity and cells that incorporate such recombinant nucleic acids and that are suitable for use in cell-based assays for the neurotoxin are provided. The encoded reporting constructs are a pair of recombinant hybrid proteins that act in concert. The reporting constructs are a pair of recombinant hybrid proteins that act in concert, and that include a botulinum neurotoxin protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- C12Q Class
- 0 % this patent is cited more than
- 1 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Feb 6, 2028 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Feb 6, 2032 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Feb 6, 2036 |
